Abstract
Background Cryptococcal meningitis (CM) accounts for about 10-20% of AIDS-defining illnesses with a 10-week mortality rate of 25-50%. Fungal load assessed by colony-forming unit (CFU) counts is used as a prognostic marker and to monitor response to treatment in research studies. PCR-based assessment of fungal load could be more rapid and less labor-intensive.
Methods We developed and validated species-specific qPCR assays based on DNA amplification of a Quorum Sensing Protein 1 (QSP1); QSP1A, QSP1 B/C, and QSP1 D that are specific to C. neoformans, C. deneoformans and C. gattii species, respectively, and a pan-Cryptococcus assay based on a multicopy 28S rRNA gene. We tested these assays for species identification (QSP1) and quantification (QSP1 ans 28S) on cerebrospinal fluid (CSF) of 209 CM patients at baseline (Day 0) and during anti-fungal therapy (Day 7 and Day 14), from the AMBITION-cm trial in Botswana and Malawi (2018-2021).
Findings When compared to quantitative cryptococcal culture (QCC) as the reference, the sensitivity of the 28S rRNA and QSP1 assays were 98.2% [95% CI: 95.1-99.5] and 90.4% [95% CI: 85.2-94.0] respectively in cerebrospinal fluid (CSF) at Day 0. Quantification of the fungal load with QSP1 and 28S rRNA qPCR correlated with QCC (R2=0.73, R2=0.78, respectively). Both Botswana and Malawi had a predominant C. neoformans prevalence of 67% [95% CI: 55, 75] and 68% [95% CI: 57, 73], respectively and lower C. gattii rates of 21% [95% CI: 14, 31] and 8% [95% CI: 4, 14], respectively. We identified 10 patients that, after 14 days of treatment, harboured viable but non-culturable yeasts based on QSP1 RNA detection (without any positive CFU in CSF culture).
Interpretation QSP1 and 28S rRNA assays are useful in identifying Cryptococcus species. qPCR results correlated well with baseline QCC and showed a similar decline in fungal load during induction therapy. These assays have a quick turnaround time and could be used in place of QCC to determine fungal load clearance. The clinical implications of the detection of possibly viable but non-culturable cells in CSF during induction therapy remain unclear.
Funding The AMBITION-cm clinical trial which was funded by the European and Developing Countries Clinical Trials Partnership; Swedish International Development Cooperation Agency; Wellcome Trust / Medical Research Council (UK) / UKAID Joint Global Health Trials and National Institute for Health Research (UK).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funded by a grant through the European Developing Countries Clinical Trials Partnership (EDCTP) supported by the Swedish International Development Cooperation Agency (SIDA) (TRIA2015-1092), and the U.K. Department of Health and Social Care, the U.K. Foreign Commonwealth and Development Office, the U.K. Medical Research Council, and Wellcome Trust, through the Joint Global Health Trials scheme (MR/P006922/1). Trial registration number: ISRCTN72509687. This work was also funded by the National Institute for Health Research (NIHR) through a Global Health Research Professorship to JNJ (RP-2017-08-ST2-012) using UK aid from the UK Government to support global health research. The funders did not influence the design, execution, and analysis of data from the study. This (publication) was made possible (in part) by a grant from Carnegie Corporation of New York. The statements made and views expressed are solely the responsibility of the author.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval The Research Ethics Committee of the London School of Hygiene and Tropical Medicine have approved the protocol v2.1 07 11 17 (ref. 14355). Approval has also been granted by the following: University of Botswana Office of Research and Development (UBR RES IRB BIO 042) Botswana Ministry of Health and Wellness Health Research and Development Division (HPDME 13 18 1); Princess Marina Hospital Research and Ethics Committee (PMH 5 79(407 1 2017) University of Cape Town Human Research Ethics Committee (642 2017) Malawi National Health Sciences Research Committee (1907) Mulago Hospital Research and Ethics Committee (MHREC 1297) the Medical Research Council of Zimbabwe (MRCZ A 2263). Any amendments was submitted and approved by each ethics committee.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All Data will be available upon request to alexandre.alanio{at}pasteur.fr
